drugset / Trial / NCT06780592
Vebreltinib Combined With Temozolomide for Glioblastoma (GBM) After Surgery
Phase 2
Not yet recruiting
60 enrolled
Huashan Hospital
Beijing Sanbo Brain Hospital · collabBeijing Tiantan Hospital · collab
RandomizedParallel-groupOpen-labelTreatment
Summary
The purpose of this study is to explore the effects of Vebreltinib in primary glioblastoma patients receiving a combination therapy of chemotherapy (temozolomidel) and MET-TKI.
Timeline
- Start
- 2025-01-13
- Primary completion
- 2025-12-31
- Completion
- 2027-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Comparator | Temozolomide | Small molecule | 150 mg/m2 | — |
| Subject | Vebreltinib | Small molecule | 300 mg | — |